📝Paper a Day… New research suggests that sodium-glucose cotransporter 2 (glucose lowering drug) inhibitors may reduce the risk of dementia in individuals with type 2 diabetes. A study from OneFlorida+ Clinical Research Network found that new users of SGLT2 inhibitors had a lower risk of all-cause dementia compared to those using sulfonylureas (another type 2 diabetes med) over a 3.2-year follow-up period. The benefits varied among subgroups, with Hispanic ethnicity and chronic kidney disease playing key roles. This highlights potential personalized approaches to dementia prevention in diabetes management. 🧠💡 #DiabetesResearch #DementiaPrevention #HealthcareInnovation 🔗: alzjournals.onlinelibrary.wiley.com/doi/10.1002/alz.14048